Tuberculosis and associated risk factors: A 5-Year review in a tertiary hospital, Kaduna Northwest Nigeria
Background: There has been different strategies in the eradication of tuberculosis worldwide and the different risk factors contributing to its occurrence need to be identified and corrected. This study set out to review and identify associated risk factors affecting the outcome of tuberculosis (TB) in a tertiary hospital in Kaduna, Nigeria.
Method: A retrospective study among patients treated for tuberculosis between January 2015 and December 2019 in a tertiary hospital, Kaduna state, North- West Nigeria. Diagnosis of tuberculosis was made if mycobacterium tuberculosis was detected in the patient’s sputum or extracellular fluid using a Ziehl-Neelsen staining technique of sputum, genexpert, radiology, biopsy of tissue specimen, doctor’s decision to treat for tuberculosis on clinical ground or a combination of these. Data was analyzed using SPSS IBM version 23.0.
A total of 1573 cases were enrolled during this period consisting of 992 (63.1%) males and 581 (36.9%) females. Their mean age was 35.78 ± 15.49 years with the age group 21-40 years 815 (51.8%) being most affected. Majority 1421 (90.3%) were new with a treatment success rate of 88.1%. Bivariate analysis revealed that age >40years (p=0.00), positive HIV status (p=0.00) and extrapulmonary site (p=0.02) had negatively affected treatment outcome.
The treatment success rate was high though some mortality noted. Efforts should be made to increase awareness of TB and more attention should be placed on patients at higher risk of poor treatment outcomes.
[ 1] Kwaghe AV, Umeokonkwo CD, Aworh KM . Evaluation of the national tuberculosis surveillance and response systems ,2018 to 2019: National Tuberculosis, Leprosy Buruli Ulcer control programme, Abuja, Nigeria. Pan African Medical Journal.2020;35:54-60 (doi:10. 11604/pamj.2020.35.54.21493)
[ 2] Seid MA, Ayalew MB, Muche EA, Gebreyohannes EA, Abegaz TM. Drug susceptible tuberculosis treatment success and associated factors in Ethiopia from 2005 to 2017: a systematic review and meta-analysis. BMJ Open 2018;8: e022111. doi:10.1136/ bmjopen-2018-022111
[ 3] Grace AG, Mittal A, Jain S, Tripathy JP, Satyanarayana S., Tharyan P. et al. Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis. Cochrane Database Syst Rev. 2018;12:12. doi: 10.1002/14651858.CD012918.pub2. PMID: 31828771; PMCID: PMC6953336
] World Health Organisation. Global Tuberculosis Control: WHO report 2016. Geneva, Switzerland: World Health Organisation, 2016. (accessed 11 Nov 2020)
[ 5] Adepoju P. Nigeria's widening tuberculosis gap. The Lancet. Infectious Diseases. 2020 Jan;20(1):29. DOI: 10.1016/s1473-3099(19)30712-1. tb2020
] Adebisi Y A, Agumage I, Sylvanus T D, Nawaila I J, Ekwere W A, et al. Burden of Tuberculosis and Challenges Facing Its Eradication in West Africa, Int J Infect. 2019 6(3): e92250. doi: 10.5812/iji.92250.
[ 7] World Health Organization. Global tuberculosis report 2019. Geneva: World Health Organization; 2019 [cited 2020 Jan 9]. Available from: https://www.who.int/tb/publications/global_report/en/
[ 8] Global tuberculosis report 2020. Geneva: World Health Organization; 2020. ISBN 978-92-4-001313-1 ( accessed 5th Mar 2021)
] World Health Organization. (2014). Global tuberculosis report 2014. World Health Organization. https://apps.who.int/iris/handle/10665/137094
] Adejumo OA, Daniel OJ, Otesanya AF, Adegbola AA, Femi-AdebayoT, Bowale A et al. Factors associated with TB/HIV Co-Infection among drug sensitive tuberculosis patients managed in a secondary health facility in Lagos, Nigeria. African journal of infectious diseases. 2017; 11(2): 75–82. https://doi.org/10.21010/ajid.v11i2.10
] World Health Organization. Fact Sheet on top 10 causes of death 2017. https://communitymedicine4assess.com/2017/02/01/who-updates-factsheet-on-top-10-causes-of-death-27-january-2017/
] Christopher C. Affusim, Emeka Kesieme, Vivien O.Abah, "The Pattern of Presentation and Prevalence of Tuberculosis in HIV-Seropositive Patients Seen at Benin City, Nigeria", International Scholarly Research Network, Pulmonology.2012; Article ID 326572. 6pages
] World Bank. Tuberculosis treatment success rate (% of new cases)/data 2019, https://data.worldbank.org/indicator/sh.tbs.cure.zs. Accessed 1 June, 2021.
] Salami, A.K. and Oluboyo, P.O. Management Outcome of Pulmonary Tuberculosis: A Nine Year Review in Ilorin. West African Journal of Medicine 2003, 22:114-119.
] Duru, C.B., Uwakwe, K.A., Nnebue, C.C., Diwe, K.C., Merenu, I.A., Emerole, C.O. et al Tuberculosis Treatment Outcomes and Determinants among Patients Treated in Hospitals in Imo State, Nigeria. Open Access Library Journal 2016, 3: e2754. http://dx.doi.org/10.4236/oalib.1102754
[ 16] World Health Organization. Guidelines for treatment of drug-susceptible tuberculosis and patient care: 2017 update. Document WHO/HTM/TB/2017. 05. Geneva, World Health Organization, 2017. https://apps.who.int/iris/ bitstream/10665/255052/1/9789241550000-eng.pdf?ua=1. Accessed 15 September, 2020.
[ 17] Federal Ministry of Health (Nigeria) 2015. National tuberculosis leprosy and Buruli ulcer management and control. Guidelines (6th edition). National TB and Leprosy control programme, Department of Public Health.
] Aysun S, Ulku Aka A, Yusuf A, Nurullah K, Nagihan Durmus K, Fatma Turan T. Factors affecting successful treatment outcomes in pulmonary tuberculosis: a single-center experience in turkey, 2005–2011. J Infect Dev Ctries. 2015;9(8):821–8. doi:10.3855/jidc.5925.
[ 19] Ofoegbu OS, Odume BB. Treatment outcome of tuberculosis patients at National Hospital Abuja Nigeria: a five year retrospective study. South African Family Practice. 2015;57(1):50-56 https://doi.org/10.1080/20786190.2014.995913
] Oyefabi A, Adetiba E, Leeshak E, Adesigbin O. Tuberculosis and the determinants of treatment outcome in Zaria, North Western Nigeria – A nine-year (2007–2015) epidemiological review. J Med Trop 2017;19:116-22
] Moses AE, Adelowo KA, Ajayi BB. Prevalence of HIV-1 infection among patients with leprosy and pulmonary tuberculosis in a semi-arid region, Nigeria. J R Soc Health 2003;123(2):117-9. doi: 10.1177/146642400312300217
] Tigist Mohammed, Kidist Daniel, Degefa Helamo,Taye Leta. Treatment outcomes of tuberculosis patients in nigist Eleni Mohammed general hospital, hosanna, southern nations, nationalities and peoples region, Ethiopia: a five year (June 2009 to August 2014) retrospective study. Arch. of Public Health 2017;75:16 https://doi.org/10.1186/s13690-017-0184-x
] Egbewale, B.E., Taiwo, S.S., Odu, O.O., Olowu, O.A. and Sobaloju, S.O. Tuberculosis Treatment Outcomes in State Hospital, Osogbo, South Western Nigeria: A Four Year Review. Nigeria Journal of Medicine 2007; 16:148-155. http://dx.doi.org/10.4314/njm.v16i2.37298
] Lefebvre, N. and Falzon, D. Risk Factors for Death among Tuberculosis Cases: Analysis of European Surveillance Data. European Respiratory Journal. 2008;31:1256-1260. http://dx.doi.org/10.1183/09031936.00131107.
] Endris M, Moges F, Belyhun Y, Woldehana E, Esmael A, Unakal C. Treatment Outcome of Tuberculosis Patients at Enfraz Health Center, Northwest Ethiopia: A five-year retrospective study. Hindawi Publishing Corporation tuberculosis research and treatment. 2014. Article ID 726193, p. 7. http://dx.doi.org/10.1155/2014/726193.
] Efegbere, H.A., Anyabolu, A.E., Onyeyili, A.N., Efegbere, E.K., Sani-Gwarzo, N., Omoniyi, A., et al. Determinants of Treatment Outcome of Public-Private Mix Tuberculosis Control Programme in South Eastern Nigeria. Afrimedic Journal, 2014; 5: 25-37.
] Moonan PK, Quitugua TN, Pogoda JM, Woo G, Drewyer G, Sahbazian B, et al. Does directly observed therapy (DOT) reduce drug resistant tuberculosis? BMC Public Health 2011; 11: 19. Epub 2011/01/11. https://doi. org/10.1186/1471-2458-11-19 PMID: 21214913
] Oge, O.K., Fashina, A.A. and Asuzu, M.C. Evaluation of the Tuberculosis Control Programme in a South Western State, Nigeria. Journal of Community Medicine & Primary Health Care 2010; 22: 41-46.
] Rasaq Adisa, Teju T. Ayandokun TT and Olusoji M. Ige. Knowledge about tuberculosis, treatment adherence and outcome among ambulatory patients with drug-sensitive tuberculosis in two directly-observed treatment centres in Southwest Nigeria. BMC Public Health 2021; 21:677 https://doi.org/10.1186/s12889-021-10698-9
] Sadana, P., Singh, T. and Deepti, S.S. Socio-Demographic Factors Affecting the Treatment Outcome in Patients of Tuberculosis. National Journal of Community Medicine, 2015; 6:609-613.
] Getahun, B., Ameni, G., Medlin, G. and Biadgilin, S. Treatment Outcome of Tuberculosis Patients under Directly Observed Treatment in Addis Ababa, Ethopia. Brazilian Journal of Infectious Diseases, 2013; 17:521-528. http://dx.doi.org/10.1016/j.bjid.2012.12.010
] Dim, C.C. and Dim, N.R. Trends of Tuberculosis Prevalence and Treatment Outcome in an under Sourced Setting: The Case of Enugu State, South East Nigeria. Nigerian Medicine Journal, 2013;54: 392-397. http://dx.doi.org/10.4103/0300-1652.126292
] Kyu HHME, Henry NJ, Mumford JE, Barber R, Shields C, et al. The global burden of tuberculosis: results from the global burden of disease study 2015. Lancet Infect Dis. 2018;18(3):261–84. https://doi.org/10.1016/S1473-3 099(17)30703-X
] Malede A, Shibabaw A, Hailemeskel A, Belay M, Asrade S. Treatment outcome of tuberculosis patients and associated risk factors at dessie and woldiya town health institutions, northeast Ethiopia: a retrospective cross-sectional study. J Bacteriol Parasitol. 2015;6:240. doi:10.4172/2155-9597.1000240.
] Gabida M, Tshimanga M, Chemhuru M, Gombe N, Bangure D. Trends for tuberculosis treatment outcomes, new sputum smear positive patients in kwekwe district, Zimbabwe, 2007–2011: a cohort analysis. J Tuberc Res. 2015; 3:126 – 35. http://dx.doi.org/10.4236/jtr.2015.34019.
] Maria de Fátima, Pessoa Militão, deAlbuquerqueRicardo, Arraes de Alencar, Ximenes Norma, Lucena-Silva Wayner, et al. Factors associated with treatment failure, dropout, and death in a cohort of tuberculosis patients (from May 2001 to July 2003) in Recife, Pernambuco State, Brazil. Cad Saude Publica. 2007;23(7):1573–82
- There are currently no refbacks.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.